Goldman resumed coverage on Relmada Therapeutics with a new price target
$RLMD
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman resumed coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $78.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2024 | $23.00 → $1.00 | Outperform → Neutral | Mizuho |
| 9/17/2024 | $3.50 → $13.00 | Hold → Buy | Jefferies |
| 6/5/2024 | $3.00 → $2.00 | Neutral → Sell | Goldman |
| 10/14/2022 | $81.00 → $8.00 | Buy → Neutral | Goldman |
| 10/14/2022 | $90.00 → $10.00 | Buy → Hold | Truist |
| 10/14/2022 | Buy → Neutral | Guggenheim | |
| 10/13/2022 | $64.00 → $7.00 | Outperform → Perform | Oppenheimer |
| 12/20/2021 | $50.00 → $42.00 | Outperform | SVB Leerink |
Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously
Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously
Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)